Enteric fever, predominantly caused by Salmonella Typhi and Salmonella Paratyphi, is a systemic illness that continues to pose significant health challenges globally. This article presents a comprehensive and updated approach to the diagnosis and treatment of this disease.
Traditionally, the diagnosis of enteric fever has relied heavily on blood culture which, despite being the gold standard, has a sensitivity of only 40-60%. Recent advancements in molecular diagnostics, such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), have shown promise in improving diagnostic accuracy. These techniques can detect bacterial DNA directly from patient samples, thereby increasing sensitivity and specificity. Serology tests, such as the Widal test, though less reliable, may be used in resource-limited settings.
Antibiotic therapy remains the mainstay of treatment for enteric fever. However, the emergence of multi-drug resistant strains necessitates careful antibiotic selection. Current guidelines recommend third-generation cephalosporins, such as ceftriaxone or cefixime, or fluoroquinolones, like ciprofloxacin, for initial empirical therapy. In cases of confirmed multi-drug resistance, azithromycin has shown efficacy. It is crucial to adjust therapy based on culture and sensitivity results to prevent treatment failure and further resistance.
Prevention strategies include improved sanitation, safe food and water practices, and vaccination. Two vaccines, Ty21a (oral) and Vi polysaccharide (injectable), are available and recommended for high-risk populations and travelers to endemic areas. However, vaccination should not replace basic hygiene practices as it provides only moderate protection.
Enteric fever remains a significant health burden, particularly in low-resource settings. While diagnostic and treatment strategies continue to evolve, emphasis should be placed on prevention and control measures to reduce the incidence of this disease. Healthcare professionals should stay abreast of current guidelines and advances to provide optimal patient care.
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Low Income, Education Tied to Depression in Older Adults
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
2.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation